CAR-T, mRNA, CRISPR, Microbiome Therapeutics

This chapter reflects the ethical, political and economic scopes of innovative biomedical innovations such as CAR-T cell therapy, mRNA techniques, and CRISPER genome editing and microbiome therapeutics within the global healthcare background. It evaluates ow state policies, market dynamics, and intellectual property regimes shape entrance, affordability and innovation trajectories in personalized medicine and reproductive machineries. The comparative innovative ecosystems of the United States, Europe, China, and India, tensions are exposed between profit driven models and public health needs. Serious ethical arguments nearby genetic manipulation, patient consent, and biomedical equity are discussed with a focus on the development of global governance, regulation and public responsibility. The inclusive and transparent framework whereby technological progress is aligned with ethical responsibility, social justice, and sustainable health outcomes worldwide.